Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AVI BioPharma receives DMD grant from Charley’s Fund
November 2007
SHARING OPTIONS:

PORTLAND, Ore.—AVI BioPharma Inc. and Charley's Fund Inc., announced that AVI has been awarded a $2.45 million research grant from Charley's Fund, a nonprofit organization that funds drug development and discovery initiatives specific to Duchenne muscular dystrophy (DMD). The award is the largest grant ever made by Charley's Fund and the largest received by AVI from a nonprofit foundation. It will support a new product development program using proprietary exon skipping technologies developed by AVI and its partner, Ercole Biotech Inc., to overcome the effects of certain genetic errors in the dystrophin gene. The award will allow AVI to accelerate its development of new therapeutics for DMD, a top priority for the company.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.